HH&L Acquisition Co.
Status: Liquidated
U=S+W/2
W=S@11.5
| IPO Proceeds, $M | $414.00M |
|---|---|
| IPO Date | Feb 5, 2021 |
| CEO | Richard Qi Li; Huanan Yang |
| Left Lead | Goldman Sachs |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 + 3 + 3 + 6 |
| IPO Sector |
Healthcare
Healthcare or healthcare-related companies in Asian markets with a focus on the Greater China market |
| IPO Geography | Asia |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
| Closing Date | Feb 12, 2024 |
HHLA
HHLA.U
HHLA/W
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on HH&L Acquisition Co.:
- Structure and cap table
- 8 directors & officers
- 30 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Kenneth W. Hitchner | 60 | Chairman |
| Richard Qi Li | 50 | CEO and Director |
| Huanan Yang | 36 | CEO and Director |
| Yingjie (Christina) Zhong | 52 | CFO |
| Qingjun Jin | 63 | Director |
| Dr. Jingwu Zhang Zang | 64 | Director |
| Professor Frederick Si Hang Ma | 68 | Director |
| Fenglei Fang | 69 | Advisor |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Goldman Sachs | Joint BR | 21,600,000 | units |
| Credit Suisse | Joint BR | 14,400,000 | |
| 36,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.